164 related articles for article (PubMed ID: 1502011)
1. Metabolism of valproate to hepatotoxic intermediates.
Baillie TA
Pharm Weekbl Sci; 1992 Jun; 14(3A):122-5. PubMed ID: 1502011
[TBL] [Abstract][Full Text] [Related]
2. Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes.
Kassahun K; Hu P; Grillo MP; Davis MR; Jin L; Baillie TA
Chem Biol Interact; 1994 Mar; 90(3):253-75. PubMed ID: 8168173
[TBL] [Abstract][Full Text] [Related]
3. Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid.
Baillie TA
Chem Res Toxicol; 1988; 1(4):195-9. PubMed ID: 2979731
[No Abstract] [Full Text] [Related]
4. Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status.
Tang W; Borel AG; Fujimiya T; Abbott FS
Chem Res Toxicol; 1995; 8(5):671-82. PubMed ID: 7548749
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial metabolism of valproic acid.
Li J; Norwood DL; Mao LF; Schulz H
Biochemistry; 1991 Jan; 30(2):388-94. PubMed ID: 1988037
[TBL] [Abstract][Full Text] [Related]
6. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. II. Influence of phenobarbital comedication.
Löscher W; Nau H; Wahnschaffe U; Hönack D; Rundfeldt C; Wittfoht W; Bojic U
Epilepsy Res; 1993 Jun; 15(2):113-31. PubMed ID: 8370349
[TBL] [Abstract][Full Text] [Related]
7. A single therapeutic dose of valproate affects liver carbohydrate, fat, adenylate, amino acid, coenzyme A, and carnitine metabolism in infant mice: possible clinical significance.
Thurston JH; Carroll JE; Hauhart RE; Schiro JA
Life Sci; 1985 Apr; 36(17):1643-51. PubMed ID: 3921791
[TBL] [Abstract][Full Text] [Related]
8. The relationship between mitochondrial activation and toxicity of some substituted carboxylic acids.
Yao KW; Mao LF; Luo MJ; Schulz H
Chem Biol Interact; 1994 Mar; 90(3):225-34. PubMed ID: 8168171
[TBL] [Abstract][Full Text] [Related]
9. In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions.
Ponchaut S; van Hoof F; Veitch K
Biochem Pharmacol; 1992 Jun; 43(11):2435-42. PubMed ID: 1610408
[TBL] [Abstract][Full Text] [Related]
10. Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates.
Rettenmeier AW; Prickett KS; Gordon WP; Bjorge SM; Chang SL; Levy RH; Baillie TA
Drug Metab Dispos; 1985; 13(1):81-96. PubMed ID: 2858383
[TBL] [Abstract][Full Text] [Related]
11. Enantiotopic differentiation during the biotransformation of valproic acid to the hepatotoxic olefin 2-n-propyl-4-pentenoic acid.
Porubek DJ; Barnes H; Meier GP; Theodore LJ; Baillie TA
Chem Res Toxicol; 1989; 2(1):35-40. PubMed ID: 2519229
[TBL] [Abstract][Full Text] [Related]
12. Studies on the beta-oxidation of valproic acid in rat liver mitochondrial preparations.
Bjorge SM; Baillie TA
Drug Metab Dispos; 1991; 19(4):823-9. PubMed ID: 1680661
[TBL] [Abstract][Full Text] [Related]
13. The toxicity of metabolites of sodium valproate in cultured hepatocytes.
Kingsley E; Gray P; Tolman KG; Tweedale R
J Clin Pharmacol; 1983 Apr; 23(4):178-85. PubMed ID: 6408143
[TBL] [Abstract][Full Text] [Related]
14. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. I. Biochemical, histopathological and pharmacokinetic studies.
Löscher W; Wahnschaffe U; Hönack D; Wittfoht W; Nau H
Epilepsy Res; 1992 Dec; 13(3):187-98. PubMed ID: 1493781
[TBL] [Abstract][Full Text] [Related]
15. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid.
Levy RH; Rettenmeier AW; Anderson GD; Wilensky AJ; Friel PN; Baillie TA; Acheampong A; Tor J; Guyot M; Loiseau P
Clin Pharmacol Ther; 1990 Sep; 48(3):225-35. PubMed ID: 2119269
[TBL] [Abstract][Full Text] [Related]
16. Amelioration of adverse effects of valproic acid on ketogenesis and liver coenzyme A metabolism by cotreatment with pantothenate and carnitine in developing mice: possible clinical significance.
Thurston JH; Hauhart RE
Pediatr Res; 1992 Apr; 31(4 Pt 1):419-23. PubMed ID: 1570210
[TBL] [Abstract][Full Text] [Related]
17. Influence of co-medication on the metabolism of valproate.
Pisani F
Pharm Weekbl Sci; 1992 Jun; 14(3A):108-13. PubMed ID: 1502008
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P-450--catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid.
Rettie AE; Rettenmeier AW; Howald WN; Baillie TA
Science; 1987 Feb; 235(4791):890-3. PubMed ID: 3101178
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of medium-chain fatty acid beta-oxidation in vitro by valproic acid and its unsaturated metabolite, 2-n-propyl-4-pentenoic acid.
Bjorge SM; Baillie TA
Biochem Biophys Res Commun; 1985 Oct; 132(1):245-52. PubMed ID: 3933498
[TBL] [Abstract][Full Text] [Related]
20. Binding of a valproate metabolite to the trifunctional protein of fatty acid oxidation.
Baldwin GS; Abbott FS; Nau H
FEBS Lett; 1996 Apr; 384(1):58-60. PubMed ID: 8797803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
